October 25, 2011
Pharmacosmos A/S, Denmark, announced today the launch of
the company's product Monofer® in Germany. The Danish company has
entered into collaboration with Medice Pharma GmbH & Co. in
The German company is responsible for the marketing of Monofer®
in Germany and joins Pharmacosmos' line of trusted
Lars Christensen, MD, President and CEO of Pharmacosmos, said: "We
are delighted to team up with Medice as our partner for Monofer® in
Germany and we look forward to the collaboration. Medice is a
highly professional company specialized in the treatment of
Richard Ammer, MD, PhD, General Manager of Medice, said: "Patients
suffering from iron deficiency anaemia will benefit from fast high
dose therapy, which will result in fewer hospital visits for
patients. Monofer® offers high dose opportunities in a single
administration and we believe Monofer® will become a very important
product in the treatment of iron deficiency anaemia in
Monofer® (iron isomaltoside 1000) is an intravenous iron compound
based on an innovative chemical structure. Monofer® is indicated
for treatment of iron deficiency anaemia and offers high dose
administration up to 20mg/kg in 15-60 minutes. Monofer® offers most
patients a full iron correction in just one visit and no test dose
is required. Iron deficiency anaemia is a global health problem and
Monofer® has the potential to cure millions of patients
Monofer® is registered in several countries and is currently
available in UK, Ireland, Denmark, Sweden, Norway, Finland,
Netherlands, Germany and Poland.
Lars Christensen, MDPresident and CEO
T: +45 59 48 59 59
Richard Ammer, MD, PhDGeneral Manager
T: +49 2371 937-0
About Medice Pharma GmbH & Co.
Medice is based in Iserlohn, Germany, and is a
fully-integrated, mid-sized family-owned pharmaceutical enterprise.
The company develops, manufactures and distributes high-quality
drugs, pharmaceutical products and medical devices throughout
Germany, Europe and key international markets and holds leading
positions in defined niche indications. Likewise, Medice has a
broad portfolio for patients with renal insufficiency and is the
first supplier with Epoetin and iron to treat anemia.
About Pharmacosmos A/S
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.